Advanced glycation end products and schizophrenia: A systematic review

Journal of Psychiatric Research

Volumn 66-67, Issue , 2015, Pages 112-117

  Kouidrat, Youssef ^a,b   Amad, Ali ^c   Arai, Makoto ^d   Miyashita, Mitsuhiro ^d   Lalau, Jean Daniel ^a   Loas, Gwenole ^e   Itokawa, Masanari ^d  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b Department of Nutrition   (France)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^e ERASME HOSPITAL   (Belgium)

Author keywords

Advanced glycation end products; Antioxidant defense system; Cardiovascular risk; Oxidative stress; RAGE; Schizophrenia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; GLUTATHIONE PEROXIDASE; GLYOXALASE; PENTOSIDINE; PYRIDOXINE; SUPEROXIDE DISMUTASE;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; HUMAN; LIFESTYLE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; METABOLISM;

GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; SCHIZOPHRENIA;

EID: 84930539896     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.04.023     Document Type: Review

References (64)

1. Angeloni C., Zambonin L., Hrelia S. Role of methylglyoxal in Alzheimer's disease. BioMed Res Int 2014, 2014:238485.
2. Arai M., Yuzawa H., Nohara I., Ohnishi T., Obata N., Iwayama Y., et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry 2010, 67(6):589-597.
3. Arroll M.A., Wilder L., Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J 2014, 13(1):91.
4. Arsov S., Graaff R., van Oeveren W., Stegmayr B., Sikole A., Rakhorst G., et al. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med CCLM FESCC 2014, 52(1):11-20.
5. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196(1):9-21.
6. Beisswenger P.J., Howell S.K., Russell G.B., Miller M.E., Rich S.S., Mauer M. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 2013, 36(10):3234-3239.
7. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry J Ment Sci 2010, 196(2):116-121.
8. Ceriello A., Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004, 24(5):816-823.
9. Chuah Y.K., Basir R., Talib H., Tie T.H., Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflamm 2013, 2013:403460.
10. Ciobica A., Padurariu M., Dobrin I., Stefanescu C., Dobrin R. Oxidative stress in schizophrenia - focusing on the main markers. Psychiatr Danub 2011, 23(3):237-245.
11. Clynes R., Moser B., Yan S.F., Ramasamy R., Herold K., Schmidt A.M. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007, 7(8):743-751.
12. Daffu G., del Pozo C.H., O'Shea K.M., Ananthakrishnan R., Ramasamy R., Schmidt A.M. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci 2013, 14(10):19891-19910.
13. DE Hert M., Correll C.U., Bobes J., Cetkovich-Bakmas M., Cohen D., Asai I., et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry Off J World Psychiatr Assoc WPA 2011, 10(1):52-77.
14. Del Turco S., Basta G. An update on advanced glycation endproducts and atherosclerosis. BioFactors Oxf Engl 2012, 38(4):266-274.
15. De Vos L.C., Mulder D.J., Smit A.J., Dullaart R.P.F., Kleefstra N., Lijfering W.M., et al. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 2014, 34(4):933-938.
16. Dipasquale S., Pariante C.M., Dazzan P., Aguglia E., McGuire P., Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. JPsychiatr Res 2013, 47(2):197-207.
17. Emanuele E., Martinelli V., Carlin M.V., Fugazza E., Barale F., Politi P. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders. Neurosci Lett 2011, 487(1):99-102.
18. Emiliani F.E., Sedlak T.W., Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry 2014, 27(3):185-190.
19. Engelen L., Stehouwer C.D.A., Schalkwijk C.G. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab 2013, 15(8):677-689.
20. Goldberg T., Cai W., Peppa M., Dardaine V., Baliga B.S., Uribarri J., et al. Advanced glycoxidation end products in commonly consumed foods. JAm Diet Assoc 2004, 104(8):1287-1291.
21. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A 2007, 104(42):16621-16626.
22. Hambsch B. Altered glyoxalase 1 expression in psychiatric disorders: cause or consequence?. Semin Cell Dev Biol 2011, 22(3):302-308.
23. Hegab Z., Gibbons S., Neyses L., Mamas M.A. Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012, 4(4):90-102.
24. Herold K., Moser B., Chen Y., Zeng S., Yan S.F., Ramasamy R., et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. JLeukoc Biol 2007, 82(2):204-212.
25. Itokawa M., Miyashita M., Arai M., Miyata T. Carbonyl stress in schizophrenia. Biochem Soc Trans 2014, 42(2):468-472.
26. Jack M., Wright D. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res 2012, 159(5):355-365.
27. Jaisson S., Gillery P. Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin Chem 2010, 56(9):1401-1412.
28. Kalea A.Z., Schmidt A.M., Hudson B.I. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci 2009, 116(8):621.
29. Katsuta N., Ohnuma T., Maeshima H., Takebayashi Y., Higa M., Takeda M., et al. Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia. Schizophr Bull 2014, 40(6):1366-1373.
30. Kizer J.R., Benkeser D., Arnold A.M., Ix J.H., Mukamal K.J., Djousse L., et al. Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults. Atherosclerosis 2014, 235(1):116-121.
31. Kouidrat Y., Amad A., Desailloud R., Diouf M., Fertout E., Scoury D., et al. Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia. JPsychiatr Res 2013, 47(8):1044-1048.
32. Kouidrat Y., Amad A., Lalau J.-D., Loas G. Eating disorders in schizophrenia: implications for research and management. Schizophr Res Treat 2014, 2014:791573.
33. Kulak A., Steullet P., Cabungcal J.-H., Werge T., Ingason A., Cuenod M., et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal 2013, 18(12):1428-1443.
34. Li J., Liu D., Sun L., Lu Y., Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. JNeurol Sci 2012, 317(1-2):1-5.
35. Loas G., Descle P., Yon V. Mortality in Kraepelinian schizophrenic patients: a prospective study with a median follow-up of 8.4 years. Compr Psychiatry 2010, 51(2):151-156.
36. Mahajan N., Dhawan V. Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases. Int J Cardiol 2013, 168(3):1788-1794.
37. Meerwaldt R., Graaff R., Oomen P.H.N., Links T.P., Jager J.J., Alderson N.L., et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004, 47(7):1324-1330.
38. Miyashita M., Arai M., Kobori A., Ichikawa T., Toriumi K., Niizato K., et al. Clinical features of schizophrenia with enhanced carbonyl stress. Schizophr Bull 2014, 40(5):1040-1046.
39. Miyashita M., Arai M., Yuzawa H., Niizato K., Oshima K., Kushima I., et al. Replication of enhanced carbonyl stress in a subpopulation of schizophrenia. Psychiatry Clin Neurosci 2014, 68(1):83-84.
40. Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. W64.
41. Ott C., Jacobs K., Haucke E., Navarrete Santos A., Grune T., Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol 2014, 2:411-429.
42. Ponath G., Schettler C., Kaestner F., Voigt B., Wentker D., Arolt V., et al. Autocrine S100B effects on astrocytes are mediated via RAGE. JNeuroimmunol 2007, 184(1-2):214-222.
43. Prasad A., Bekker P., Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev 2012, 20(4):177-183.
44. Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol Off Publ Int Coll Angiol Inc 2014, 23(1):11-16.
45. Rabbani N., Xue M., Thornalley P.J. Activity, regulation, copy number and function in the glyoxalase system. Biochem Soc Trans 2014, 42(2):419-424.
46. Ramasamy R., Schmidt A.M. Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep 2012, 9(2):107-116.
47. Saruwatari J., Yasui-Furukori N., Kamihashi R., Yoshimori Y., Oniki K., Tsuchimine S., et al. Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia. Neuropsychiatr Dis Treat 2013, 9:1683-1698.
48. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511(7510):421-427. Schizophrenia Working Group of the Psychiatric Genomics Consortium.
49. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44(2):129-146.
50. Steiner J., Bernstein H.-G., Schiltz K., Müller U.J., Westphal S., Drexhage H.A., et al. Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog Neuropsychopharmacol Biol Psychiatry 2014, 48:287-294.
51. Steiner J., Walter M., Wunderlich M.T., Bernstein H.-G., Panteli B., Brauner M., et al. Anew pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009, 65(12):1107-1110.
52. Stirban A., Gawlowski T., Roden M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol Metab 2014, 3(2):94-108.
53. Sugamura K., Keaney J., John F. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011, 51(5):978-992.
54. Sweeting J., Duflou J., Semsarian C. Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year review. Schizophr Res 2013, 150(2-3):398-403.
55. Uribarri J., Woodruff S., Goodman S., Cai W., Chen X., Pyzik R., et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. JAm Diet Assoc 2010, 110(6). 911-6.e12.
56. Vancampfort D., Wampers M., Mitchell A.J., Correll C.U., De Herdt A., Probst M., et al. Ameta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry Off J World Psychiatr Assoc WPA 2013, 12(3):240-250.
57. Van Os J., Kapur S. Schizophrenia. Lancet 2009, 374(9690):635-645.
58. Vistoli G., De Maddis D., Cipak A., Zarkovic N., Carini M., Aldini G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013, 47(Suppl.1):3-27.
59. Wang J., Zou L., Song Z., Lang X., Huang S., Lu F., et al. Meta-analysis of RAGE gene polymorphism and coronary heart disease risk. PLoS One 2012, 7(12):e50790.
60. Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:200-206.
61. Yamagishi S., Maeda S., Matsui T., Ueda S., Fukami K., Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta 2012, 1820(5):663-671.
62. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22(1-2):83-93.
63. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998, 32(1):1-8.
64. Zimmermann U., Kraus T., Himmerich H., Schuld A., Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. JPsychiatr Res 2003, 37(3):193-220.